Smokeless tobacco and cigarettes confer similar adverse vascular health risks

A new study(opens in new tab/window) in the American Journal of Preventive Medicine(opens in new tab/window), published by Elsevier, investigated the incidence of peripheral artery disease (PAD) among users of smokeless tobacco products. The findings show that the use of chewing tobacco and snuff is associated with a two-fold increase in the risk for PAD.

“We’ve long known about the link between cigarette smoking and cardiovascular disease and PAD. There is much less information available about the harmful effects of noncombustible forms of tobacco and nicotine exposure. Building on prior research associating smokeless tobacco use with heart disease and stroke, our results link use of these products to a higher incidence of PAD,” explained lead investigator Jeremy R. Van’t Hof, MD, MS, Lillehei Heart Institute & Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.

The investigators evaluated data from 14,344 participants in the Atherosclerosis Risk in Communities (ARIC) Study, which has followed adults in United States since the late 1980s. The average age of participants at the beginning of study was 54.1, 54.8% were female, and 26.4% were Black.

The research characterized adults by smokeless tobacco use and cigarette smoking and then analyzed who developed PAD by identifying hospitalizations with diagnosis codes for PAD or leg revascularization. After adjusting for sociodemographic and cardiovascular risk factors, smokeless tobacco use was associated with a two-fold increased risk for PAD. This increased risk was only seen in individuals who were not currently smoking at the beginning of the study.

The rate of PAD diagnoses was 4.4 per 1,000 person years among the smokeless tobacco users and 3.4 per 1,000 person years for current cigarette smokers. In comparison, there were only 1.3 cases of PAD per 1,000 person years for individuals who had never used smokeless tobacco products and were not currently smoking cigarettes. Notably, there was no incremental increase in risk for participants who used smokeless tobacco and also smoked cigarettes. This may be because the risk of PAD from cigarette smoking is strong enough that adding an additional tobacco exposure did little to adjust that risk.

Public health efforts have successfully reduced cigarette smoking in the US over the past 30 years, but smokeless tobacco use is on the rise, with 2.4% of adults reporting use of smokeless tobacco products in 2019. Noncombustible tobacco products are often viewed as “clean” nicotine delivery systems and considered less harmful than cigarettes, leading some to advocate for their use in smoking cessation. “While smokeless tobacco products may not expose people to the noxious effects of combustion, our study shows that they nonetheless have an adverse impact on vascular health. It is important for clinicians to understand these health implications, screen patients for all forms of tobacco and nicotine use, and counsel accordingly,” Dr. Van’t Hof advised. Noting that uncertainty remains about the net benefit versus harm of vaping, he explained that the study did not evaluate e-cigarettes because the baseline ARIC data was collected before they were introduced.

---

Notes for editors

The article is “Association of Smokeless Tobacco Use With Incident Peripheral Artery Disease: Results From the Atherosclerotic Risk in Communities Study,” by Jeremy R. Van’t Hof, MD, MS, Wendy Wang, MPH, Kunihiro Matsushita, MD, PhD, Gerardo Heiss, MD, PhD, Aaron R. Folsom, MD, MPH, Rachel Widome, PhD, and Pamela L. Lutsey, PhD (https://doi.org/10.1016/j.amepre.2023.01.001(opens in new tab/window)). It appears online in advance of the American Journal of Preventive Medicine, volume 64, issue 5 (May 2023), published by Elsevier. The article is openly available for 30 days at https://www.ajpmonline.org/article/S0749-3797(23)00002-8/fulltext(opens in new tab/window). Full text of this article is also available to credentialed journalists upon request; contact Jillian B. Morgan at +1 734 936 1590 or [email protected](opens in new tab/window). Journalists wishing to interview the authors should contact Media Relations, University of Minnesota Medical School, at [email protected](opens in new tab/window). The research was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services under contract 75N92022D00003.

About the American Journal of Preventive Medicine

The American Journal of Preventive Medicine(opens in new tab/window) is the official journal of the American College of Preventive Medicine(opens in new tab/window) and the Association for Prevention Teaching and Research(opens in new tab/window). It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials. 

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation(opens in new tab/window), we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.